Publications

Our scientific and clinical findings have been presented and published in prestigious peer-reviewed forums, and a selection of these have been curated for reference.

Latest Publications

Date Program Title of Publication
MAY 2018 HEPLISAV-B

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

Vaccine. 2018 May 3;36(19):2604-2611
Hyer R, McGuire DK, Xing B, Jackson S, Janssen R.

OCT 2016 HEPLISAV-B

Development of the CpG Adjuvant 1018: A Case Study

Vaccine Adjuvants (Methods Mol Biol.) 2017;1494:15-27
Campbell JD

JUL 2015 HEPLISAV-B

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.

Vaccine. 2015 Jul 17;33(31):3614-8.
Janssen JM, Jackson S, Heyward WL, Janssen RS.

FEB 2015 HEPLISAV-B

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.

Vaccine. 2015 Feb 11;33(7):833-7
Janssen JM, Heyward WL, Martin JT, Janssen RS.

HEPLISAV-B

Date Program Title of Publication
MAY 2018 HEPLISAV-B

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

Vaccine. 2018 May 3;36(19):2604-2611
Hyer R, McGuire DK, Xing B, Jackson S, Janssen R.

OCT 2016 HEPLISAV-B

Development of the CpG Adjuvant 1018: A Case Study

Vaccine Adjuvants (Methods Mol Biol.) 2017;1494:15-27
Campbell JD

JUL 2015 HEPLISAV-B

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.

Vaccine. 2015 Jul 17;33(31):3614-8.
Janssen JM, Jackson S, Heyward WL, Janssen RS.

FEB 2015 HEPLISAV-B

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.

Vaccine. 2015 Feb 11;33(7):833-7
Janssen JM, Heyward WL, Martin JT, Janssen RS.

NOV 2013 HEPLISAV-B

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.

Vaccine. 2013 Nov 4;31(46):5306-13.
Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT.

NOV 2013 HEPLISAV-B

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age.

Vaccine. 2013 Nov 4;31(46):5300-5.
Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT.

AUG 2012 HEPLISAV-B

Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.

Vaccine, 2012; 30(36):5445-5448.
Scott A. Halperin, Shelly McNeil, Joanne M. Langley, Bruce Smith, Donna MacKinnon-Cameron, Robyn McCall-Sani, William L. Heyward, J. Tyler Martin.

MAR 2012 HEPLISAV-B

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age.

Vaccine, 2012; 30(15): 2556-2563.
Scott A. Halperin, Brian Ward, et al.

MAR 2012 HEPLISAV-B

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.

Vaccine, 2012; 30(16): 2689-2696.
Benjamin P. Sablan, Dong Joon Kim et al

TLR Biology vaccine

Date Program Title of Publication
APR 2016 TLR Biology vaccine

Optimization, Production, and Characterization of a CpGOligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen

Bioconjugate Chemistry, 2016, 27, 1293−1304, DOI: 10.1021/acs.bioconjchem.6b00107
Bob Milley, Radwan Kiwan, Gary S. Ott, Carlo Calacsan, Melissa Kachura, John D. Campbell, Holger Kanzler, and Robert L. Coffman

DEC 2015 TLR Biology vaccine

A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys

The Journal of Immunology, 2016; 196:284-297; Prepublished online 25 November 2015; doi: 10.4049/jimmunol.1501903
Melissa A. Kachura, Colin Hickle et al.

JUL 2011 TLR Biology

Assessing the safety of adjuvanted vaccines.

Sci. Transl. Med., 2011; 3(93):93rv2.
Ahmed SS, Plotkin SA, Black S, Coffman RL.

FEB 2011 TLR Biology

Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response.

Immunity, 2011; 34(3):375-384.
Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, DeFranco AL.

OCT 2010 TLR Biology

Vaccine adjuvants: putting innate immunity to work.

Immunity, 2010; 33(4):492-503.
Coffman, RL, Sher A, Seder RA.

AUG 2009 TLR Biology

CpG-containing immunostimulatory DNA sequences elicit TNF-α–dependent toxicity in rodents but not in humans.

J. Clin. Invest., 2009; 119(9):2564–2576.
John D. Campbell, Yan Cho, et al.

JAN 2009 TLR Biology

Signalling pathways leading to IFN-a production in human PDC and the possible use of agonists or antagonists of TLR-7 and TLR-9 in clinical indications (Review).

J. Intern. Med., 2009; 265:43-57.
Guiducci C, Coffman RL, Barrat FJ (Dynavax Technologies Corporation, Berkeley, CA USA).

MAY 2007 TLR Biology

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.

Nature Medicine, 2007; 13(5):552-559.
Holger Kanzler, Franck J Barrat, Edith M Hessel & Robert L Coffman.

SEP 2006 TLR Biology

Toll-like Receptor Recognition Regulates Immunodominance in an Antimicrobial CD4+ T Cell Response.

Immunity, 2006; 25:665-664.
Felix Yarovinsky, Holger Kanzler, Sara Hieny, Robert L. Coffman, and Alan Sher.

AUG 2006 TLR Biology

Properties Regulating the Nature of the Plasmacytoid Dendritic Cell Response to TLR9 Activation.

J. Exp. Med., 2006; 203(8):1999-2008.
Cristiana Guiducci, Gary Ott, Jean H. Chan, Emily Damon, Carlo Calacsan, Tracy Matray, Kyung-Dall Lee, Robert L. Coffman and Franck J. Barrat.

JAN 2006 TLR Biology

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.

Vaccine, 2006; 24(1): 20-26.
Scott A. Halperin, Simon Dobson et al.

FEB 2005 TLR Biology

Superior Activity of the Type C Class of ISS In Vitro and In Vivo Across Multiple Species.

DNA Cell Biol., 2005; 24(2):63-72.
Marshall, J.D., K.L. Fearon, et al.

AUG 2004 TLR Biology

CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells.

J. Immunol., 2004; 173(3):1647-1657.
Teleshova, N., J. Kenney, J. Jones, J. Marshall, G. Van Nest, J. Dufour, R. Bohm, J.D. Lifson, A. Gettie, and M. Pope.

JUN 2004 TLR Biology

Polymyxin B enhances ISS-mediated immune responses across multiple species.

Cell. Immunol., 2004; 229(2):93-105.
Marshall, J.D., D. Higgins, C. Abbate, P. Yee, G. Teshima, G. Ott, T. Dela Cruz, D. Passmore, K.L. Fearon, S. Tuck, and G. Van Nest.